Services

EnquBio's Comprehensive Drug Discovery Solutions & Services

At EnquBio, our expert team delivers high quality, efficient, and dependable R&D solutions that enable pharmaceutical and biotech partners to advance and expand their drug development pipelines.

Exploratory Clinical Sample Analysis

Turn limited, high-value clinical and preclinical samples into integrated biomarker and pharmacodynamic insight.

EnquBio analyzes exploratory clinical samples — serum, plasma, PBMCs and whole blood from clinical research cohorts — as well as preclinical study samples, across multiple analytical platforms. Studies run under established SOPs with documented sample receipt and chain of custody. EnquBio is not a GLP or CLIA laboratory: analyses are fit-for-purpose and exploratory, which keeps studies faster and more cost-efficient than regulated bioanalysis, supporting research and translational decision-making rather than regulatory submission or clinical diagnosis.

Exploratory clinical sample analysis at EnquBio

One Sample Set. Multiple Biological Readouts.

A single program can combine cellular, soluble-protein, protein-signaling and molecular biomarker endpoints.

Cellular Biomarkers

Cell identity and functional state

  • Immunophenotyping
  • Activation / differentiation
  • Target expression
  • Receptor occupancy
  • Intracellular signaling
Soluble Protein Biomarkers

Secreted and circulating proteins

  • Cytokines
  • Chemokines
  • Growth factors
  • Soluble receptors
  • Pharmacodynamic biomarkers
Protein Expression & Signaling

Protein-level pathway responses

  • Total protein expression
  • Phosphoproteins
  • Protein degradation
  • Cleavage / processing
  • Pathway modulation
Molecular Biomarkers

Targeted nucleic-acid analysis

  • Gene expression
  • Absolute quantification
  • Copy number
  • Molecular PD markers
  • Target knockdown confirmation
A single study can combine multiple biomarker modalities to provide a more complete view of treatment response.

Start With the Sample, Not the Platform

The analytical strategy is selected after considering the biology, matrix, available volume, target abundance, throughput and required sensitivity.

01

Biological Question

What decision should the biomarker data support?

02

Sample Constraints

What matrix, volume, cell number, viability and storage history are available?

03

Biomarker Strategy

Which cellular, protein and molecular endpoints are most informative?

04

Analytical Approach

Which platform—or combination of platforms—best answers the question?

Preclinical to Translational Research

Biomarker strategies can follow the program from model systems into human research samples.

Preclinical

Study-derived animal and model samples

Support biomarker endpoints generated alongside in vivo and other preclinical studies.

  • Whole blood, serum and plasma
  • Tissues and tumor samples
  • Splenocytes / immune cells
  • Study-derived supernatants
Translational

Human ex vivo and disease-relevant samples

Bridge preclinical biology with human cellular and molecular responses.

  • PBMCs and whole blood
  • Primary human cells
  • Disease-relevant donor samples
  • Ex vivo stimulated samples
Exploratory Clinical Research

Client-provided human research samples

Analyze predefined biomarker endpoints in appropriately handled research specimens.

  • Serum and plasma
  • PBMCs
  • Whole-blood-derived samples
  • Other project-specific specimens
Exploratory research-use sample analysis; not intended for diagnostic use.

The Sample Journey

From initial sample review to integrated reporting.

01

Sample & Study Review

Matrix, volume, storage, sample number, design and target list.

02

Biomarker Strategy

Define the most informative cellular, protein and molecular endpoints.

03

Assay Selection

Match method to sensitivity, matrix, throughput and sample constraints.

04

Sample Analysis

Execute fit-for-purpose workflows with appropriate controls and QC.

05

Integrated Interpretation

Evaluate cross-platform changes in the context of biology, dose and time.

06

Data Package & Report

Deliver processed data, QC information and study-level conclusions.

Sample Types

Study design is adapted to the biological matrix and available sample material.

Blood-Derived

  • Whole blood
  • PBMCs
  • Serum
  • Plasma

Cell-Based

  • Primary cells
  • Immune-cell cultures
  • Cell pellets
  • Culture supernatants

Tissue-Derived

  • Tumor tissue
  • Normal tissue
  • Tissue lysates
  • Tissue homogenates

Study-Specific Samples

  • Preclinical study samples
  • Ex vivo treated samples
  • Client-provided research specimens
  • Other fit-for-purpose matrices

Integrated Multi-Platform Analysis

Different assay modalities can be combined within one study to build a more complete biological picture.

Flow CytometryCell phenotype, activation, signaling
ImmunoassaysCytokines and soluble biomarkers
Western / JessProtein expression and pathway signaling
RT-qPCR / ddPCRGene expression and molecular biomarkers
↓
Integrated Biological Interpretation

What Clients Receive

A practical data package designed to support program decisions.

Processed Assay DataAnalyzed biomarker results in a study-ready format.
QC ReviewAssay performance and quality-control assessment.
Flow Gating / PlotsGating strategy and representative cellular biomarker outputs where applicable.
Standard Curves & Assay QCRelevant quantitative assay performance information.
Cross-Platform InterpretationIntegrated review of cellular, protein and molecular endpoints.
Study ReportScientific summary and interpretation aligned to project scope.

Why EnquBio

Integrated biomarker support built around biological questions and valuable samples.

Multi-Platform CapabilityCellular, protein and molecular biomarkers within one program.
Sample-Conscious DesignMethods selected around available volume and biological value.
Scientist-Led InterpretationResults reviewed in the context of mechanism and study design.
Integrated Preclinical SupportBiomarkers can connect directly with in vitro, ex vivo and in vivo work.
Flexible Study ModelsStandalone sample analysis or integrated project support.
SOP-Driven OperationsDocumented sample receipt, chain of custody, processing and assay QC.

Frequently Asked Questions

Can a non-GLP laboratory analyze clinical samples?
Yes. Exploratory, research-use analysis of clinical research samples does not require GLP or CLIA certification. EnquBio analyzes appropriately consented human research specimens under established SOPs for biomarker and pharmacodynamic endpoints. Data support research and translational decisions; they are not used for regulatory submission or patient diagnosis.

What is the difference between exploratory and regulated (GLP/CLIA) bioanalysis?
Regulated bioanalysis follows full method validation and compliance requirements needed for regulatory submission or clinical reporting, which adds time and cost. Exploratory analysis uses fit-for-purpose qualification matched to the research question — typically faster and more cost-efficient — and is the appropriate level of rigor for biomarker discovery and exploratory endpoints.

Which platforms can be applied to clinical research samples?
Depending on the endpoint, samples can be analyzed by MSD and other immunoassays, ProteinSimple Jess, RT-qPCR and ddPCR, and multicolor flow cytometry — individually or combined within one study.

Have samples, but not yet a biomarker strategy?

Send us your sample type, available volume, study design and biological question. Our scientists can recommend an integrated fit-for-purpose analysis plan.

Contact Our Scientists →
Standalone or integrated sample analysis
Cellular, protein and molecular biomarker readouts
Preclinical, translational and exploratory research support